VNRXNYSEIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
VOLITIONRX LTD
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.17−0.01 (-3.50%)
Close on Oct 19, 2026
- Market cap
- $1.59M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-1258.5%+156917.8 pts over 5 years
Net margin
-1352.2%+150507.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +40.0% | +78.0% | +164.1% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -87.5% | -133.8% | 79.0% | |
| Return on assets | -73.4% | -86.0% | -286.6% | |
| Current ratio | 10.82 | 3.26 | 0.17 | |
| Debt to equity | 0.02 | 0.21 | -0.20 | |
| Net debt to EBITDA | 1.75× | 0.78× | -0.27× | |
| Interest coverage | -610.0× | -163.7× | – | |
| Capex to revenue | – | 14449.9% | 5.2% | |
| Diluted shares | 1M | 2M | 5M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Volitionrx generated $99.77M from operations and spent $4.03M on capital expenditure, dividends and share buybacks. 99% of that went back into the business.
Generated
$99.77M
Used
$4.03M
Capital expenditure$3.99M99%Dividends$00%Share buybacks$31.77K1%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1352.2%
×Asset turnover0.21×
×Equity multiplier-0.28×
=Return on equity, FY202579.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -1352.2% | 0.21× | -0.28× | 79.0% |
| FY2024 | -2186.3% | 0.07× | -1.14× | 164.9% |
| FY2023 | -4601.7% | 0.03× | -4.46× | 687.6% |
| FY2022 | -9986.7% | 0.01× | 3.02× | -404.0% |
| FY2021 | -29977.0% | 0.00× | 1.58× | -158.7% |
| FY2020 | -151859.6% | 0.00× | 1.56× | -133.8% |
| FY2019 | -94168.5% | 0.00× | 1.47× | -122.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$23.36M
- Cash generatingOperating cash flow above zero-$19.68M
- Return on assets improvedROA up on the prior year-96.5% → -248.5%
- Earnings backed by cashOperating cash flow above net income-$19.68M vs -$23.36M
- Less leverageLong-term debt to assets fell42.1% → 84.3%
- Better liquidityCurrent ratio rose0.52 → 0.17
- No dilutionShare count did not rise4M → 5M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.04 → 0.18